Investors

Latest Report

2015 - Q3 Quarterly Report

ProMetic Reports its Third Quarter 2015 Highlights and Financial Results
- Cash position of $42.5 million
- 2015 year-to-date product sales of $9.2 million compared to $7.3 million in 2014
- Plasminogen shown as safe, well tolerated and efficacious in a plasminogen deficient patient

Download

Annual Report

Annual Report 2014

Building a company to bring safer therapeutic products.

Download Link

Presentation

September 2015 Corporate Presentation

Experts in bioseparation, plasma derived and small molecule drugs.

Download Link

Upcoming Events

There are no events. Please check back again later

Latest News

X